regorafenib (STIVARGA°) and gastrointestinal stromal tumours after treatment failure

October 2015
Prescrire International;Oct2015, Vol. 24 Issue 164, p234
No abstract available.


Related Articles

  • Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours. Shirley, Matt; Keating, Gillian // Drugs;Jun2015, Vol. 75 Issue 9, p1009 

    Regorafenib (Stivarga) is an orally administered small molecule inhibitor of multiple protein kinases, including kinases involved in oncogenesis and tumour angiogenesis. It was initially approved for use in patients with previously treated metastatic colorectal cancer. Based on the findings of...

  • Regorafenib Tablets (Stivarga®). Elliott, William T.; Chan, James // Internal Medicine Alert;4/15/2013, Vol. 35 Issue 7, p53 

    The article reports on the approval by the Food and Drug Administration of an oral multikinase inhibitor regorafenib which is marketed by Bayer HealthCare Pharmaceuticals as Stivarga, for the treatment of metastatic colorectal cancer and advanced gastrointestinal stromal tumors.

  • Regorafenib: A Guide to Its Use in Advanced Gastrointestinal Stromal Tumor (GIST) After Failure of Imatinib and Sunitinib. Lyseng-Williamson, Katherine // BioDrugs;2013, Vol. 27 Issue 5, p525 

    Regorafenib (Stivarga), a new inhibitor of multiple kinases, is indicated as third-line treatment in patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib and sunitinib in the USA. In a phase III trial in...

  • Regorafenib.  // Reactions Weekly;Aug2015, Vol. 1563 Issue 1, p183 

    The article presents a case study of a 50-year-old female patient who developed acute liver failure after consuming regorafenib for the treatment of her gastrointestinal stromal tumuor.

  • BAYER'S STIVARGA (REGORAFENIB) APPROVED IN THE EU.  // Biotech Business;Oct2013, Vol. 26 Issue 10, p3 

    This article reports that BayerHealthCare, a subgroup of the German chemical and pharmaceutical company Bayer AG, has secured approval of the European Commission for its Stivarga (regorafenib) tablets for the treatment of adult patients with metastatic colorectal cancer (mCRC). The U.S. and...

  • Regorafenib: A Review of Its Use in Previously Treated Patients with Progressive Metastatic Colorectal Cancer. Carter, Natalie // Drugs & Aging;Jan2014, Vol. 31 Issue 1, p67 

    Regorafenib (Stivarga) is an inhibitor of multiple protein kinases, including those involved in oncogenesis, tumour angiogenesis and maintenance of the tumour microenvironment. The drug is approved as monotherapy for the treatment of metastatic colorectal cancer (mCRC) in patients who have...

  • FDA Update.  // Oncology Nurse Advisor;Mar/Apr2013, Vol. 4 Issue 2, p10 

    The article discusses cancer drugs that were approved by the U.S. Food and Drug Administration as of March 2013 including Kadcyla or ado-trastuzumab emtansine for breast cancer, Stivarga or regorafenib for advanced gastrointestinal stromal tumors, and Pomalyst or pomalidomide for multiple myeloma.

  • Regorafenib.  // Reactions Weekly;Aug2014, Vol. 1513 Issue 1, p31 

    The article present a case study of a 61-year-old man who developed hyperammonaemic encephalopathy after receiving regorafenib during the treatment of progressed metastatic gastrointestinal stromal tumor (GIST).

  • Imatinib.  // Reactions Weekly;11/6/2010, Issue 1326, p20 

    This article describes a case study involving a 53-year-old woman who developed liver failure during treatment with imatinib for gastrointestinal stromal tumours.

  • Imatinib.  // Reactions Weekly;Nov2014, Vol. 1528 Issue 1, p108 

    The article presents a case study of a 66-year-old woman who developed erythema multiforme after treatment with imatinib for gastrointestinal stromal tumour.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics